SAN FRANCISCO, March 5, 2019 /PRNewswire/ -- Invitae
Corporation (NYSE: NVTA) today announced the pricing of an
underwritten public offering of 9,000,000 shares of its common
stock at a price to the public of $19.00 per share. All of the shares are
being sold by Invitae. The gross proceeds to Invitae from the
offering, before deducting the underwriting discounts and
commissions and other offering expenses, are expected to be
$171.0 million. The offering is
expected to close on or about March 8,
2019, subject to customary closing conditions. In addition,
Invitae has granted the underwriters a 30-day option to purchase up
to an additional 1,350,000 shares of its common stock at the public
offering price, less underwriting discounts and commissions.
J.P. Morgan Securities LLC, Cowen and Company, LLC and SVB
Leerink LLC are acting as the book-running managers for the
offering.
An automatic shelf registration statement relating to the shares
was filed with the Securities and Exchange Commission and became
effective on March 4, 2019. A copy of
the final prospectus supplement and accompanying prospectus
relating to the offering, when available, may be obtained from J.P.
Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY
11717, or by telephone at (866) 803-9204, or by email at
prospectus-eq_fi@jpmchase.com; or from Cowen and Company, LLC,
c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, or by
telephone at (631) 274-2806; or from SVB Leerink LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at (800)
808-7525, ext. 6132, or by email at syndicate@svbleerink.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Invitae Corporation
Invitae Corporation (NYSE: NVTA) is a leading genetics company
whose mission is to bring comprehensive genetic information into
mainstream medicine to improve healthcare for billions of people.
Invitae's goal is to aggregate the world's genetic tests into a
single service with higher quality, faster turnaround time, and
lower prices.
Forward-Looking Statements
This press release contains forward-looking statements within
the Private Securities Litigation Reform Act of 1995, including
statements relating to Invitae's expectations regarding the
completion, timing and size of the public offering, and its
expectations with respect to granting the underwriters a 30-day
option to purchase additional shares. Actual results or
developments may differ materially from those projected or implied
in these forward-looking statements. Factors that may cause such a
difference include risks and uncertainties related to completion of
the public offering on the anticipated terms or at all, market
conditions and the satisfaction of customary closing conditions
related to the public offering. More information about the risks
and uncertainties faced by Invitae is contained in the section
captioned "Risk factors" in the preliminary prospectus supplement
related to the public offering filed with the Securities and
Exchange Commission. Invitae disclaims any intention or obligation
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Contact:
Laura D'Angelo
ir@invitae.com
(628) 213-3369
View original content to download
multimedia:http://www.prnewswire.com/news-releases/invitae-announces-pricing-of-public-offering-of-common-stock-300807367.html
SOURCE Invitae Corporation